Aktienanalyse zu Polyrizon Ltd (PLRZ)PLRZPolyrizon Ltd

Polyrizon Ltd is an Israel-based biotechnology company. The Company is primarily engaged and specializing in the development of medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Its naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a biological mask with a thin shield containment barrier in the nasal cavity. The Company is focused not only on the development of intranasal products, but also on commercialization. The Company cooperates with medical specialists and researchers.. It operates in the Healthcare sector.

Polyrizon Ltd. is a good buy right now due to its recent clinical trial initiation for NASARIX, which targets seasonal allergic rhinitis, and a strong 1-year price increase of 110.72%. The current price of $11.05 is significantly below its 52-week high of $18.20, indicating potential for growth. However, the company has reported significant losses, with a net income of -3,158,000 USD in Q4 2025, which presents a risk.